We are live on ! Find out more
ATOS icon

Atossa Therapeutics
ATOS

14 hedge funds and large institutions have $471K invested in Atossa Therapeutics in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more capital inflows, than outflows

Capital inflows: $81.2K | Capital outflows: $25K

0.42% more ownership

Funds ownership: 2.87% → 3.29% (+0.42%)

7% less funds holding

Funds holding: 15 → 14 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
14
Holders Change
-1
Holders Change %
-6.67%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
–
Closed
4
Calls
$17K
Puts
–
Net Calls
+$17K
Net Calls Change
-$7K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$41K
2
VF
Virtu Financial
New York
+$23K
3
Deutsche Bank
Deutsche Bank
Germany
+$10K
4
UBS Group
UBS Group
Switzerland
+$7.18K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$22K
2
Victory Capital Management
Victory Capital Management
Texas
-$3K

ATOS Hedge Fund Activity: Q4 2019 in Review

14 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2019, worth a combined $471K — down 8.2% from $513K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ATOS and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $41K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $22K sold.

  • 14 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2019, down from 15 in Q3 2019.
  • Funds reported $471K of Atossa Therapeutics stock for Q4 2019, down 8.2% quarter-over-quarter.
  • 3 funds opened new Atossa Therapeutics positions in Q4 2019 and 4 closed out, a net change of -1 holder.
  • The largest Atossa Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $41K added.
  • The largest Atossa Therapeutics seller in Q4 2019 was JP Morgan Chase, an estimated $22K sold.

Based on aggregated 13F filings for Q4 2019.